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Background
Inhaled nitric oxide (NO) is a potent and selective pulmo-
nary vasodilator. NO induces cGMP synthesis by activat-
ing soluble guanylate cyclase (sGC) in ventilated lung
regions. Carbon monoxide (CO) has also been proposed
to modulate smooth muscle tone via activation of sGC.
We tested the hypotheses that direct stimulation of sGC
by BAY 41-2272 would produce pulmonary vasodilation
and augment the pulmonary responses to inhaled NO or
CO.
Materials and Methods
In awake lambs instrumented with vascular catheters and
a tracheostomy tube, the thromboxane analog U-46619
was administered i.v. to increase mean pulmonary arterial
pressure (PAP) to 35 mmHg. In 7 lambs, BAY 41-2272
was i.v. infused at incremental doses of 0.03, 0.1, and 0.3
mg/kg/h. Another 8 lambs received i.v. L-NAME followed
by BAY 41-2272 at 0.1 mg/kg/h. In two additional study
groups, NO gas at 2, 10, and 20 ppm (n = 8) or CO gas at
50, 250, and 500 ppm (n = 4) was administered via inha-
lation in a random sequence. Infusion of BAY 41-2272 at
0.1 mg/kg/h was then commenced; the doseof U-46619
was adjusted to maintain PAP at 35 mmHg; and NO or
CO was again administered.
Results
BAY 41-2272 reduced PAP and pulmonary vascular resist-
ance and increased transpulmonary cGMP release in a
dose-dependent manner. Larger doses of BAY 41-2272
produced systemic vasodilation and elevated the cardiac
index. L-NAME abolished the systemic but not the pulmo-
nary vasodilator effects of BAY 41-2272. Furthermore,
infusing BAY 41-2272 markedly potentiated and pro-
longed the pulmonary vasodilation produced by inhaled
NO. In contrast, inhaled CO had no effect on pulmonary
vasoconstriction before or during administration of BAY
41-2272.
Conclusion
In lambs with acute pulmonary hypertension, BAY 41-
2272 is a potent pulmonary vasodilator that augments
and prolongs the pulmonary vasodilator response to
inhaled NO. Direct pharmacological stimulation of sGC,
either alone or in combination with inhaled NO, may
provide a novel approach for the treatment of pulmonary
hypertension.
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